ENTRADA THERAPEUTICS, INC.: share-based compensation expense
Share-based compensation expense for ENTRADA THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ENTRADA THERAPEUTICS, INC. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 19,609,000 | USD | 2026-02-26 | 10-K · 0001689375-26-000011 |
| 2024-01-01 | 2024-12-31 | 17,915,000 | USD | 2026-02-26 | 10-K · 0001689375-26-000011 |
| 2023-01-01 | 2023-12-31 | 13,111,000 | USD | 2025-02-27 | 10-K · 0001689375-25-000011 |
| 2022-01-01 | 2022-12-31 | 9,895,000 | USD | 2024-03-13 | 10-K · 0001689375-24-000016 |
| 2021-01-01 | 2021-12-31 | 2,526,000 | USD | 2023-03-06 | 10-K · 0001689375-23-000019 |
| 2020-01-01 | 2020-12-31 | 325,000 | USD | 2022-03-15 | 10-K · 0001558370-22-003614 |
Related financial histories
- ENTRADA THERAPEUTICS, INC.: total assets
- ENTRADA THERAPEUTICS, INC.: total liabilities
- ENTRADA THERAPEUTICS, INC.: stockholders equity
- ENTRADA THERAPEUTICS, INC.: cash and cash equivalents
- ENTRADA THERAPEUTICS, INC.: net income or loss
- ENTRADA THERAPEUTICS, INC.: operating cash flow
- ENTRADA THERAPEUTICS, INC.: capital expenditure payments
- ENTRADA THERAPEUTICS, INC.: contract revenue excluding tax
- ENTRADA THERAPEUTICS, INC.: financing cash flow
- ENTRADA THERAPEUTICS, INC.: investing cash flow
- ENTRADA THERAPEUTICS, INC.: retained earnings or deficit
- ENTRADA THERAPEUTICS, INC.: basic weighted-average shares
- ENTRADA THERAPEUTICS, INC.: diluted weighted-average shares
- ENTRADA THERAPEUTICS, INC.: basic earnings per share
- ENTRADA THERAPEUTICS, INC.: diluted earnings per share
- ENTRADA THERAPEUTICS, INC.: income tax expense or benefit
- ENTRADA THERAPEUTICS, INC.: net property, plant and equipment
- ENTRADA THERAPEUTICS, INC.: operating income or loss
- ENTRADA THERAPEUTICS, INC.: current assets
- ENTRADA THERAPEUTICS, INC.: current liabilities
- ENTRADA THERAPEUTICS, INC.: current accounts payable
- ENTRADA THERAPEUTICS, INC.: operating expenses
- ENTRADA THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- ENTRADA THERAPEUTICS, INC. / CIK 0001689375
- Captured
- 2026-09-21T17:23:57.606Z
- SEC response SHA-256
bc7821f434adfb8a3b14fdb2aaf9e37f9d5a6f8ea2f4be3b4b557c511276031d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001689375.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))